Citations (230)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (28)
Indrajit Ghosh, Hiten Gutka, Mary E. Krause, Ryan Clemens & Ramesh S. Kashi. (2023) A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations. mAbs 15:1.
Read now
Read now
Tianyu Si, Xiaolin Ma, Wenwei Zhu & Yongming Zhou. (2023) Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis. Hematology 28:1.
Read now
Read now
Robert J. Connor, Renee Clift & David W. Kang. (2023) Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model. Drug Delivery 30:1.
Read now
Read now
B. Rama & A. J. Ribeiro. (2023) Role of nanotechnology in the prolonged release of drugs by the subcutaneous route. Expert Opinion on Drug Delivery 20:5, pages 559-577.
Read now
Read now
Advait V Badkar, Rajesh B Gandhi, Shawn P Davis & Michael J LaBarre. (2021) Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements. Drug Design, Development and Therapy 15, pages 159-170.
Read now
Read now
Stephen P. Knowles, Marie A. Printz, David W. Kang, Michael J. LaBarre & Renee P. Tannenbaum. (2021) Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery. Expert Opinion on Drug Delivery 18:11, pages 1673-1685.
Read now
Read now
Barry Paul, Shebli Atrash, Manisha Bhutani, Peter Voorhees, Issam Hamadeh & Saad Z. Usmani. (2020) An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma. Expert Review of Hematology 13:8, pages 795-802.
Read now
Read now
Joana A. D. Sequeira, Ana C. Santos, João Serra, Catarina Estevens, Raquel Seiça, Francisco Veiga & António J. Ribeiro. (2019) Subcutaneous delivery of biotherapeutics: challenges at the injection site. Expert Opinion on Drug Delivery 16:2, pages 143-151.
Read now
Read now
Kenneth W. Locke, Daniel C. Maneval & Michael J. LaBarre. (2019) ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Delivery 26:1, pages 98-106.
Read now
Read now
Yoosoo Yang, Yeonsun Hong, Eunji Cho, Gi Beom Kim & In-San Kim. (2018) Extracellular vesicles as a platform for membrane-associated therapeutic protein delivery. Journal of Extracellular Vesicles 7:1.
Read now
Read now
Nirav D. Raichura, Md Shahid Alam, V. V. Jaichandran, Saurabh Mistry & Bipasha Mukherjee. (2018) Hyaluronidase allergy mimicking orbital cellulitis. Orbit 37:2, pages 149-153.
Read now
Read now
Zhaoyang Li & Rachael Easton. (2018) Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. mAbs 10:1, pages 18-33.
Read now
Read now
Anni Pan, Zhaoyang Wang, Binlong Chen, Wenbing Dai, Hua Zhang, Bing He, Xueqing Wang, Yiguang Wang & Qiang Zhang. (2018) Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft. Drug Delivery 25:1, pages 1495-1503.
Read now
Read now
Yanan Cui, Ping Cui, Binlong Chen, Suxin Li & Hua Guan. (2017) Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Development and Industrial Pharmacy 43:4, pages 519-530.
Read now
Read now
Christina Theodore-Oklota, Louise Humphrey, Christof Wiesner, Gabriel Schnetzler, Stacie Hudgens & Alicyn Campbell. (2016) Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. Patient Preference and Adherence 10, pages 1767-1776.
Read now
Read now
Igor-Wolfgang Blau, Niall Conlon, Robert Petermann, Nikolai Nikolov & Torben Plesner. (2016) Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies. Expert Review of Clinical Immunology 12:7, pages 705-711.
Read now
Read now
Richard T North, Vernon J Harvey, Levonne C Cox & Stuart N Ryan. (2015) Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. ClinicoEconomics and Outcomes Research 7, pages 423-430.
Read now
Read now
David Aguiar-Bujanda, María Jesús Blanco-Sánchez, María Hernández-Sosa, Saray Galván-Ruíz & Samuel Hernández-Sarmiento. (2015) Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. Cancer Management and Research 7, pages 319-330.
Read now
Read now
Philippe Solal-Celigny. (2015) Rituximab by subcutaneous route. Expert Review of Hematology 8:2, pages 147-153.
Read now
Read now
Simon Rule, Graham P. Collins & Kunal Samanta. (2014) Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. Journal of Medical Economics 17:7, pages 459-468.
Read now
Read now
Salima Hamizi, Gilles Freyer, Naoual Bakrin, Emilie Henin, Amina Mohtaram, Olivia Le Saux & Claire Falandry. (2013) Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer. OncoTargets and Therapy 6, pages 89-94.
Read now
Read now
Stephen Jolles. (2013) Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. ImmunoTargets and Therapy 2, pages 125-133.
Read now
Read now
Marcelo Sandoval, Patricia Coleman, Rahim Govani, Saima Siddiqui & Knox H. Todd. (2013) Pilot Study of Human Recombinant Hyaluronidase–Enhanced Subcutaneous Hydration and Opioid Administration for Sickle Cell Disease Acute Pain Episodes. Journal of Pain & Palliative Care Pharmacotherapy 27:1, pages 10-18.
Read now
Read now
Sharifa Al-Zahrani, Marija Zaric, Cian McCrudden, Chris Scott, Adrien Kissenpfennig & Ryan F Donnelly. (2012) Microneedle-mediated vaccine delivery: Harnessing cutaneous immunobiology to improve efficacy. Expert Opinion on Drug Delivery 9:5, pages 541-550.
Read now
Read now
Yanan Zheng, Devin B. Tesar, Lisa Benincosa, Herbert Birnböck, C. Andrew Boswell, Daniela Bumbaca, Kyra J Cowan, Dimitry M. Danilenko, Ann L. Daugherty, Paul J. Fielder, Hans Peter Grimm, Amita Joshi, Nicole Justies, Gerry Kolaitis, Nicholas Lewin-Koh, Jing Li, Sami McVay, Jennifer O'Mahony, Michael Otteneder, Michael Pantze, Wendy S. Putnam, Zhihua J. Qiu, Jane Ruppel, Thomas Singer, Oliver Stauch, Frank-Peter Theil, Jennifer Visich, Jihong Yang, Yong Ying, Leslie A. Khawli & Wolfgang F. Richter. (2012) Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs 4:2, pages 243-255.
Read now
Read now
Rong Deng, Feng Jin, Saileta Prabhu & Suhasini Iyer. (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?. Expert Opinion on Drug Metabolism & Toxicology 8:2, pages 141-160.
Read now
Read now
George Harb, Francois Lebel, Jean Battikha & Jeffrey W. Thackara. (2010) Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Current Medical Research and Opinion 26:2, pages 279-288.
Read now
Read now
Amber L Dunn, James E Heavner, Gabor Racz & Miles Day. (2010) Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management. Expert Opinion on Biological Therapy 10:1, pages 127-131.
Read now
Read now
Articles from other publishers (202)
P. A. Zeynalova, O. L. Timofeeva, Yu. E. Ryabukhina, F. M. Abbasbeyli, N. A. Kupryshina, A. G. Zhukov & T. T. Valiev. (2023) Use of daratumumab drug formulation for subcutaneous administration in multiple myeloma therapy: Literature review and clinical observation. MD-Onco 3:4, pages 16-27.
Crossref
Crossref
Naoual Dahmana, Pierre-Louis Destruel, Samantha Facchetti, Vanessa Braun, Vanessa Lebouc, Zana Marin, Sulabh Patel & Gregoire Schwach. (2023) Reversible protein complexes as a promising avenue for the development of high concentration formulations of biologics. International Journal of Pharmaceutics 648, pages 123616.
Crossref
Crossref
Maria Dimou, Matthaios Speletas, Cinzia Milito, Aleksandra Pyzik, Dörte Huscher, Marta Kamieniak, David Pittrow & Michael Borte. (2023) Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis. Cancers 15:18, pages 4524.
Crossref
Crossref
Peter Leidenmühler, Joris Höfinghoff, Norbert Haider, Gerald Brachtl, Markus Weiller, Ivan Bilic & Bagirath Gangadharan. (2023) In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins. Drug Delivery and Translational Research 13:9, pages 2367-2377.
Crossref
Crossref
Gregory Jones, Lingxue Zeng & Jonghan Kim. (2023) Application of Allometric Scaling to Nanochelator Pharmacokinetics. ACS Omega 8:30, pages 27256-27263.
Crossref
Crossref
Beate Bittner, Manuel Sánchez-Félix, Dennis Lee, Athanas Koynov, Joshua Horvath, Felix Schumacher & Simon Matoori. (2023) Drug delivery breakthrough technologies – A perspective on clinical and societal impact. Journal of Controlled Release 360, pages 335-343.
Crossref
Crossref
Mona Purcell, Sahab Babaee, Michael Galluppi, John Cline, Guangli Hu, Ioan Petrescu, Jennifer Hughes, Meredith Allen, Eric Messina, Steven Persak, Yogita Krishnamachari, Ashley Lay-Fortenbery & Corin O. Miller. (2023) Characterization of large volume subcutaneous injections using computed tomography imaging and simultaneous pressure measurements. Frontiers in Drug Delivery 3.
Crossref
Crossref
Marliese Alexander, Kim Jachno, Kelly-Anne Phillips, John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe & Senthil Lingaratnam. (2023) Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis. Journal of Oncology Pharmacy Practice.
Crossref
Crossref
Sofia Bruni, María Florencia Mercogliano, Florencia Luciana Mauro, Rosalia Inés Cordo Russo & Roxana Schillaci. (2023) Cancer immune exclusion: breaking the barricade for a successful immunotherapy. Frontiers in Oncology 13.
Crossref
Crossref
Evi B. Struble, Jonathan M. O. Rawson, Tzanko Stantchev, Dorothy Scott & Marjorie A. Shapiro. (2023) Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies. Pharmaceutics 15:5, pages 1538.
Crossref
Crossref
Markus Blümel, Jing Liu, Isabella de Jong, Sarah Weiser, Jonas Fast, Jennifer Litowski, Melissa Shuman, Shyam B. Mehta, Leanne Amery, David Cheng Thiam Tan, Feng Jia, Dushyant Shekhawat, Camille Dagallier, Mina Emamzadeh, Annette Medina, Camilla Santos, Florian Gasser & Christian Urban. (2023) Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products. Journal of Pharmaceutical Sciences.
Crossref
Crossref
Anurag Purushothaman, Mohammad Mohajeri & Tanmay P. Lele. (2023) The role of glycans in the mechanobiology of cancer. Journal of Biological Chemistry 299:3, pages 102935.
Crossref
Crossref
Beate Bittner. (2023) Customer-centric product presentations for monoclonal antibodies. AAPS Open 9:1.
Crossref
Crossref
Arti Singh, Kamaljeet Singh, Jagriti Rana, Upasna Singh, Anirrud Sharma & Vineet Kumar. (2023) Vision-threatening reactions of hyaluronidase after local anesthesia: A case series and review of literature. Indian Journal of Ophthalmology - Case Reports 3:3, pages 888-891.
Crossref
Crossref
Wanshan Hu, Tingting Peng, Yao Huang, Tao Ren, Hongyu Chen, Yangyan Chen, Disang Feng, Chuanbin Wu & Xin Pan. (2023) Hyaluronidase-powered microneedles for significantly enhanced transdermal delivery efficiency. Journal of Controlled Release 353, pages 380-390.
Crossref
Crossref
Zhaoyang Li, Kristin Follman, Ed Freshwater, Frank Engler & Leman Yel. (2022) Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies. International Immunopharmacology 113, pages 109331.
Crossref
Crossref
Hao Lou, Mei Feng & Michael J. Hageman. (2022) Advanced Formulations/Drug Delivery Systems for Subcutaneous Delivery of Protein-Based Biotherapeutics. Journal of Pharmaceutical Sciences 111:11, pages 2968-2982.
Crossref
Crossref
Ting-ting Chen, Ming-ming Yuan, Yu-mei Tao, Xiao-yan Ren & Sufen Li. (2021) Engineering of Self-assembly Polymers Encapsulated with Dual Anticancer Drugs for the Treatment of Endometrial Cancer. Journal of Cluster Science 33:6, pages 2661-2671.
Crossref
Crossref
Marie A. Printz, Barry J. Sugarman, Rudolph D. Paladini, Michael C. Jorge, Yan Wang, David W. Kang, Daniel C. Maneval & Michael J. LaBarre. (2022) Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration. The AAPS Journal 24:6.
Crossref
Crossref
Alexandre Bordat, Tanguy Boissenot, Nada Ibrahim, Marianne Ferrere, Manon Levêque, Léa Potiron, Stéphanie Denis, Sébastien Garcia-Argote, Olivia Carvalho, Jérôme Abadie, Catherine Cailleau, Grégory Pieters, Nicolas Tsapis & Julien Nicolas. (2022) A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs. Journal of the American Chemical Society 144:41, pages 18844-18860.
Crossref
Crossref
Ehsan Rahimi, Hector Gomez & Arezoo M. Ardekani. (2022) Transport and distribution of biotherapeutics in different tissue layers after subcutaneous injection. International Journal of Pharmaceutics 626, pages 122125.
Crossref
Crossref
Xizhe Gao, Jongbong Lee, Kiran Deshpande, David W. Kang, Anas M. Fathallah & Leonid Kagan. (2022) Mechanistic Modeling of the Effect of Recombinant Human Hyaluronidase (rHuPH20) on Subcutaneous Delivery of Cetuximab in Rats. Pharmaceutical Research 39:8, pages 1867-1880.
Crossref
Crossref
Zita Chovancová. (2022) Clinical experience with facilitated subcutaneous immunoglobulin treatment. Klinická farmakologie a farmacie 36:2, pages 38-42.
Crossref
Crossref
Bo Pang, Jing He, Weijiao Zhang, Hao Huang, Yang Wang, Miao Wang, Guocheng Du & Zhen Kang. (2022) Active Expression of Human Hyaluronidase PH20 and Characterization of Its Hydrolysis Pattern. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Kris Dammen-Brower, Paige Epler, Stanley Zhu, Zachary J. Bernstein, Paul R. Stabach, Demetrios T. Braddock, Jamie B. Spangler & Kevin J. Yarema. (2022) Strategies for Glycoengineering Therapeutic Proteins. Frontiers in Chemistry 10.
Crossref
Crossref
Laia Alsina, J. Bruno Montoro, Pedro Moral Moral, Olaf Neth, Marta Ortiz Pica, Silvia Sánchez-Ramón, María Presa, Itziar Oyagüez, Miguel Ángel Casado & Luis Ignacio González-Granado. (2021) Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. The European Journal of Health Economics 23:3, pages 551-558.
Crossref
Crossref
Nafiseh Sanei Ata-abadi, Mahboobeh Forouzanfar, Kianoush Dormiani, Shiva Rouhollahi Varnosfaderani, Leila Pirjamali, Mohammad Hossein Nasr-Esfahani & Reza Moradi Hajidavaloo. (2022) Site-specific integration as an efficient method for production of recombinant human hyaluronidase PH20 in semi-adherent cells. Applied Microbiology and Biotechnology 106:4, pages 1459-1473.
Crossref
Crossref
Carol M. MacLean, Zona Godsafe, Pablo Soto‐Forte & Finn Larsen. (2021) Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate, a Novel Gonadotropin‐Releasing Hormone Antagonist, in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 11:2, pages 257-269.
Crossref
Crossref
Wang Wang Lee & Claire M. Patterson. 2022. Biopharmaceutics. Biopharmaceutics
253
263
.
Wendy D. Woodley, Didier R. Morel, Diane E. Sutter, Ronald J. Pettis & Natasha G. Bolick. (2021) Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults. Clinical and Translational Science 15:1, pages 92-104.
Crossref
Crossref
Beate Bittner & Johannes Schmidt. 2022. Formulation and Device Lifecycle Management of Biotherapeutics. Formulation and Device Lifecycle Management of Biotherapeutics
1
46
.
Beate Bittner & Johannes Schmidt. 2022. Formulation and Device Lifecycle Management of Biotherapeutics. Formulation and Device Lifecycle Management of Biotherapeutics
153
174
.
Yahya Gul, Hasan Kapakli, Sukru Nail Guner, Havva Bozkurt Alan, Esra Hazar, Sevgi Keles & Ismail Reisli. (2021) Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight. Journal of Clinical Immunology 42:1, pages 64-71.
Crossref
Crossref
Maitri Bhatt & Pravin Shende. (2021) Modulated approaches for strategic transportation of proteins and peptides via ocular route. Journal of Drug Delivery Science and Technology 66, pages 102835.
Crossref
Crossref
Michael J. Dolton, Aaron Chesterman, Anita Moein, Kaycee M. Sink, Ariel Waitz, Kathleen Blondeau, Geoffrey A. Kerchner, Nan Hu, Logan Brooks, Monica K. Wetzel‐Smith, Amanda Roden, Ajay Deshmukh, Kun Peng, Montserrat Carrasco‐Triguero, Jill Smith, Susanne Ostrowitzki & Angelica Quartino. (2021) Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers. Clinical Pharmacology & Therapeutics 110:5, pages 1337-1348.
Crossref
Crossref
David S. Monahan, Talal Almas, Robert Wyile, Faisal H. Cheema, Garry P. Duffy & Aamir Hameed. (2021) Towards the use of localised delivery strategies to counteract cancer therapy–induced cardiotoxicities. Drug Delivery and Translational Research 11:5, pages 1924-1942.
Crossref
Crossref
Abhay TharmattDanish MalhotraHamayal SharmaNeena Bedi. (2021) Pharmaceutical Perspective in Wearable Drug Delivery Systems. ASSAY and Drug Development Technologies 19:6, pages 386-401.
Crossref
Crossref
Sneha PervinSomsubhra GhoshSankhadip BoseNandan Sarkar. (2021) Human immune globulin 10% with recombinant human Hyaluronidase-
A Review. Research Journal of Pharmacy and Technology, pages 4504-4508.
Crossref
Crossref
Hao Lou, Cory Berkland & Michael J. Hageman. (2021) Simulating particle movement inside subcutaneous injection site simulator (SCISSOR) using Monte-Carlo method. International Journal of Pharmaceutics 605, pages 120824.
Crossref
Crossref
David W. Kang, Beate Bittner, Barry J. Sugarman, Monica L. Zepeda & Marie A. Printz. (2021) Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer. PLOS ONE 16:7, pages e0254765.
Crossref
Crossref
Luiza Helena Gremski, Fernando Hitomi Matsubara, Nayanne Louise Costacurta Polli, Bruno Cesar Antunes, Pedro Henrique de Caires Schluga, Hanna Câmara da Justa, João Carlos Minozzo, Ana Carolina Martins Wille, Andrea Senff-Ribeiro & Silvio Sanches Veiga. (2021) Prospective Use of Brown Spider Venom Toxins as Therapeutic and Biotechnological Inputs. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Peng Hou, Fudan Zheng, Clairissa D. Corpstein, Lei Xing & Tonglei Li. (2021) Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Sensitivity Analysis. Pharmaceutical Research 38:6, pages 1011-1030.
Crossref
Crossref
Jessica A. Cowell, Marie A. Printz & Curtis B. Thompson. (2021) Recombinant human hyaluronidase PH20-mediated dermal spreading activity in mice is not altered by steroids, antihistamines, or salicylic acid. Drug Metabolism and Drug Interactions 36:2, pages 155-163.
Crossref
Crossref
Andrea Allmendinger. (2021) Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products. Pharmaceutical Research 38:5, pages 739-757.
Crossref
Crossref
Min-Jeong Kwoen, Yong-Hoon Choi, Keun-Suh Kim, Na-Hee Chang, Young-Kyun Kim & Hyo-Jung Lee. (2021) Efficacy of local hyaluronidase administration in guided bone regeneration surgery: a randomized controlled trial. Journal of the Korean Association of Oral and Maxillofacial Surgeons 47:2, pages 91-98.
Crossref
Crossref
Jennifer J. Gao, Christy L. Osgood, Yutao Gong, Hui Zhang, Erik W. Bloomquist, Xiling Jiang, Junshan Qiu, Jingyu Yu, Pengfei Song, Nam Atiqur Rahman, Haw-Jyh Chiu, Tiffany K. Ricks, Fatima Rizvi, Sherry Hou, Willie Wilson, Abde M. Abukhdeir, Jeffrey Seidman, Soma Ghosh, Reena Philip, William F. Pierce, Vishal Bhatnagar, Paul G. Kluetz, Richard Pazdur, Julia A. Beaver & Laleh Amiri-Kordestani. (2021) FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer. Clinical Cancer Research 27:8, pages 2126-2129.
Crossref
Crossref
Ava M. Vargason, Aaron C. Anselmo & Samir Mitragotri. (2021) The evolution of commercial drug delivery technologies. Nature Biomedical Engineering 5:9, pages 951-967.
Crossref
Crossref
Fudan Zheng, Peng Hou, Clairissa D. Corpstein, Lei Xing & Tonglei Li. (2021) Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Model Development. Pharmaceutical Research 38:4, pages 607-624.
Crossref
Crossref
Ajai Chari, Paula Rodriguez‐Otero, Helen McCarthy, Kenshi Suzuki, Vania Hungria, Anna Sureda Balari, Aurore Perrot, Cyrille Hulin, Hila Magen, Shinsuke Iida, Vladimir Maisnar, Lionel Karlin, Ludek Pour, Dolly A. Parasrampuria, Tara Masterson, Michele Kosh, Shiyi Yang, Maria Delioukina, Ming Qi, Robin Carson & Cyrille Touzeau. (2020) Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study. British Journal of Haematology 192:5, pages 869-878.
Crossref
Crossref
Ahil N. Ganesh, Carolyn Heusser, Sudhakar Garad & Manuel Vicente Sánchez-Félix. (2021) Patient-centric design for peptide delivery: Trends in routes of administration and advancement in drug delivery technologies. Medicine in Drug Discovery 9, pages 100079.
Crossref
Crossref
Nicole L. Jarvi & Sathy V. Balu-Iyer. (2021) Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins. BioDrugs 35:2, pages 125-146.
Crossref
Crossref
Hao Lou & Michael J. Hageman. (2021) Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies. Pharmaceutical Research 38:3, pages 451-460.
Crossref
Crossref
Galen H. Shi, Robert J. Connor, David S. Collins & David W. Kang. (2021) Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans. AAPS PharmSciTech 22:1.
Crossref
Crossref
Hirohiko Shibayama, Morio Matsumoto, Hiroshi Kosugi, Kazuhiro Shibayama, Hiroshi Yamazaki & Shinsuke Iida. (2020) Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma. International Journal of Hematology 113:1, pages 112-121.
Crossref
Crossref
Hsiangkuo Yuan & Stephen D. Silberstein. 2021. Monoclonal Antibodies in Headache. Monoclonal Antibodies in Headache
25
42
.
Manuel Sánchez-Félix, Matt Burke, Hunter H. Chen, Claire Patterson & Sachin Mittal. (2020) Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge. Advanced Drug Delivery Reviews 167, pages 66-77.
Crossref
Crossref
Robert J. Connor, Darin M. Taverna, Karla Thrall, Michael J. LaBarre & David W. Kang. (2020) Use of computed tomography to assess subcutaneous drug dispersion with recombinant human hyaluronidase PH20 in a swine model. Journal of Pharmacological and Toxicological Methods 106, pages 106936.
Crossref
Crossref
Melissa Holstein, Jessica Hung, Hasin Feroz, Swarnim Ranjan, Cheng Du, Sanchayita Ghose & Zheng Jian Li. (2020) Strategies for high‐concentration drug substance manufacturing to facilitate subcutaneous administration: A review. Biotechnology and Bioengineering 117:11, pages 3591-3606.
Crossref
Crossref
Francesca Angelotti, Riccardo Capecchi, Daiana Giannini, Ornella Mazzarella, Valeria Rocchi & Paola Migliorini. (2020) Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(®)) in immunodeficiency diseases: real-life data from a monocentric experience. Clinical and Experimental Medicine 20:3, pages 387-392.
Crossref
Crossref
Robert J. Connor, Barbara Blouw, Jessica Cowell, Kelly Chen, Chunmei Zhao & David W. Kang. (2020) A Preclinical Investigation into the Effects of Aging on Dermal Hyaluronan Properties and Reconstitution Following Recombinant Human Hyaluronidase PH20 Administration. Dermatology and Therapy 10:3, pages 503-513.
Crossref
Crossref
Soohyun Kim, Iman Jalilian, Sara M. Thomasy, Morgan A. W. Bowman, Vijay Krishna Raghunathan, Yeonju Song, Cynthia A. Reinhart-King & Christopher J. Murphy. (2020) Intrastromal Injection of Hyaluronidase Alters the Structural and Biomechanical Properties of the Corneal Stroma. Translational Vision Science & Technology 9:6, pages 21.
Crossref
Crossref
David S. Collins, Manuel Sánchez-Félix, Advait V. Badkar & Randall Mrsny. (2020) Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. Journal of Controlled Release 321, pages 475-482.
Crossref
Crossref
Terri Lynn Shigle & Qaiser Bashir. (2020) Advancement in monoclonal antibody therapy for multiple myeloma. The Lancet Haematology 7:5, pages e354-e355.
Crossref
Crossref
John P. Koulakis, Joshua Rouch, Nhan Huynh, Holden H. Wu, James C. Y. Dunn & Seth Putterman. (2020) Tumescent Injections in Subcutaneous Pig Tissue Disperse Fluids Volumetrically and Maintain Elevated Local Concentrations of Additives for Several Hours, Suggesting a Treatment for Drug Resistant Wounds. Pharmaceutical Research 37:3.
Crossref
Crossref
Marie A. Printz, Samuel S. Dychter, Emanuel P. DeNoia, Rena Harrigan, Barry J. Sugarman, Monica Zepeda, Jennifer Souratha, David W. Kang & Daniel C. Maneval. (2020) A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. Current Therapeutic Research 93, pages 100604.
Crossref
Crossref
Agnès Portron, Paul Jordan, Kristy Draper, Christopher Muenzer, Daniel Dickerson, Thijs van Iersel & Carsten Hofmann. (2020) A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers. Clinical Therapeutics 42:1, pages 108-120.e1.
Crossref
Crossref
Daniel C. Maneval, Chris L. Caster, Celine Derunes, Kenneth W. Locke, Mann Muhsin, Sybille Sauter, Rose E. Sekulovich, Curtis B. Thompson & Michael J. LaBarre. 2020. Polymer-Protein Conjugates. Polymer-Protein Conjugates
175
204
.
Mohamed A. Megahed, Hossam S. El-Sawy & Khalid M. El-Say. 2020. Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents. Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents
69
103
.
Qingyan Hu, Bowen Jiang, Dingjiang Liu, Xiaolin (Charlie) Tang, Thomas Daly & Mohammed Shameem. 2020. Development of Biopharmaceutical Drug-Device Products. Development of Biopharmaceutical Drug-Device Products
343
372
.
Ian K. Styles, Orlagh M. Feeney, Tri-Hung Nguyen, Daniel H.S. Brundel, David W. Kang, Renee Clift, Michelle P. McIntosh & Christopher J.H. Porter. (2019) Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. Journal of Controlled Release 315, pages 85-96.
Crossref
Crossref
Thomas J. Bell, Oliver J. Brand, David J. Morgan, Samira Salek-Ardakani, Christopher Jagger, Toshifumi Fujimori, Lauren Cholewa, Viranga Tilakaratna, Jörgen Östling, Matt Thomas, Anthony J. Day, Robert J. Snelgrove & Tracy Hussell. (2019) Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biology 80, pages 14-28.
Crossref
Crossref
Mário L de Lemos & Anne Dar Santos. (2018) Clinical considerations of hyaluronidase as an adjunct to subcutaneous rituximab injection. Journal of Oncology Pharmacy Practice 25:4, pages 964-965.
Crossref
Crossref
Aaron C. Anselmo, Yatin Gokarn & Samir Mitragotri. (2018) Non-invasive delivery strategies for biologics. Nature Reviews Drug Discovery 18:1, pages 19-40.
Crossref
Crossref
Lin Niu, Leonard Y. Chu, Scott A. Burton, Kris J. Hansen & Jayanth Panyam. (2019) Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response. Journal of Controlled Release 294, pages 268-278.
Crossref
Crossref
Gregor Cornelius Weber, Bettina Alexandra Buhren, Holger Schrumpf, Johannes Wohlrab & Peter Arne Gerber. 2019. Therapeutic Enzymes: Function and Clinical Implications. Therapeutic Enzymes: Function and Clinical Implications
255
277
.
Gianfranco Vitiello, Giacomo Emmi & Boaz Palterer. 2019. Humoral Primary Immunodeficiencies. Humoral Primary Immunodeficiencies
275
289
.
Rong Deng, C. Andrew Boswell, Wendy S. Putnam, Meina T. Tang, Amit Garg, Chunze Li, Shan Chung & Sandhya Girish. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
151
190
.
Patrick Garidel & Ingo Presser. 2019. Lyophilization of Pharmaceuticals and Biologicals. Lyophilization of Pharmaceuticals and Biologicals
291
325
.
David J. Morgan, Joshua Casulli, Christine Chew, Emma Connolly, Sylvia Lui, Oliver J. Brand, Rizwana Rahman, Christopher Jagger & Tracy Hussell. (2018) Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia. Frontiers in Immunology 9.
Crossref
Crossref
Milvia Zambetti, Filippo Montemurro, Paolo Morandi, Claudio Zamagni, Alba A. Brandes, Giancarlo Bisagni, Katia Cagossi, Carmelo Bengala, Stefania Gori, Claudio Iannacone, Alessia Stell & Luca Gianni. (2018) Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. European Journal of Cancer 105, pages 61-70.
Crossref
Crossref
V. Gervasi, R. Dall Agnol, S. Cullen, T. McCoy, S. Vucen & A. Crean. (2018) Parenteral protein formulations: An overview of approved products within the European Union. European Journal of Pharmaceutics and Biopharmaceutics 131, pages 8-24.
Crossref
Crossref
Beate Bittner, Wolfgang Richter & Johannes Schmidt. (2018) Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs 32:5, pages 425-440.
Crossref
Crossref
Margarida Viola, Joana Sequeira, Raquel Seiça, Francisco Veiga, João Serra, Ana C. Santos & António J. Ribeiro. (2018) Subcutaneous delivery of monoclonal antibodies: How do we get there?. Journal of Controlled Release 286, pages 301-314.
Crossref
Crossref
Myoung Jin Ho, Dae Ro Lee, Sung Hyun Im, Jeong A Yoon, Chang Yong Shin, Hyun Jung Kim, Sun Woo Jang, Young Wook Choi, Young Taek Han & Myung Joo Kang. (2018) Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery. European Journal of Pharmaceutics and Biopharmaceutics 130, pages 143-151.
Crossref
Crossref
Garrett T. ShumateRajesh Chopra, Derek Jones, Darin J. MessinaChristopher K. Hee. (2018) In Vivo Degradation of Crosslinked Hyaluronic Acid Fillers by Exogenous Hyaluronidases. Dermatologic Surgery 44:8, pages 1075-1083.
Crossref
Crossref
Onur Koç & Nuray Er. (2018) Can Hyaluronidase Be an Alternative Postoperative Anti-edema Agent to Dexamethasone? Preliminary Results of an Animal Study. Journal of Oral and Maxillofacial Surgery 76:8, pages 1653-1659.
Crossref
Crossref
Sahar Awwad & Ukrit Angkawinitwong. (2018) Overview of Antibody Drug Delivery. Pharmaceutics 10:3, pages 83.
Crossref
Crossref
Samuel Luke Hill & Andrew Davies. (2018) Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Future Oncology 14:17, pages 1691-1699.
Crossref
Crossref
Massimo Radin, Dario Roccatello, Simone Baldovino & Savino Sciascia. (2018) Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris. BMJ Case Reports, pages bcr-2017-223302.
Crossref
Crossref
Preeti Yadav, Victoria M. McLeod, Cameron J. Nowell, Laura I. Selby, Angus P.R. Johnston, Lisa M. Kaminskas & Natalie L. Trevaskis. (2018) Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery. Journal of Controlled Release 272, pages 17-28.
Crossref
Crossref
Yaocun Yue, Dandan Zhao & Qiuwen Yin. (2018) Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: In vitro and in vivo anesthesia evaluation. Biomedicine & Pharmacotherapy 98, pages 813-820.
Crossref
Crossref
Ruiqi Ma, Qian Li, Zhongfeng Wang, Yifei Yuan, Lu Gan & Jiang Qian. (2018) Modulation of hyaluronan polymer size regulates proliferation of perimysial fibroblasts in thyroid eye disease. Biochemical and Biophysical Research Communications 496:4, pages 1376-1381.
Crossref
Crossref
Abhirup Mandal, Dhananjay Pal, Vibhuti Agrahari, Hoang My Trinh, Mary Joseph & Ashim K. Mitra. (2018) Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Advanced Drug Delivery Reviews 126, pages 67-95.
Crossref
Crossref
Sanna Rosengren, Jennifer Souratha, Dave Conway, Douglas B. Muchmore & Barry J. Sugarman. (2018) Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects. BioDrugs 32:1, pages 83-89.
Crossref
Crossref
Gary J Doherty, Margaret Tempero & Pippa G Corrie. (2018) HALO-109–301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncology 14:1, pages 13-22.
Crossref
Crossref
Sandor Kerpel-Fronius. (2018) A short review of the pharmacokinetic behavior of biological medicinal agents for the clinical practice. Microchemical Journal 136, pages 270-274.
Crossref
Crossref
Torben Biester, Olga Kordonouri & Thomas Danne. (2017) Pharmacological Properties of Faster-Acting Insulin Aspart. Current Diabetes Reports 17:11.
Crossref
Crossref
Hanns‐Christian Mahler & Andrea Allmendinger. 2017. Protein Therapeutics. Protein Therapeutics
469
491
.
Lora Hamuro, Grzegorz Kijanka, Francis Kinderman, Harald Kropshofer, De-xiu Bu, Monica Zepeda & Vibha Jawa. (2017) Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins. Journal of Pharmaceutical Sciences 106:10, pages 2946-2954.
Crossref
Crossref
Patrick Garidel, Alexander B. Kuhn, Lars V. Schäfer, Anne R. Karow-Zwick & Michaela Blech. (2017) High-concentration protein formulations: How high is high?. European Journal of Pharmaceutics and Biopharmaceutics 119, pages 353-360.
Crossref
Crossref
Richard L Wasserman. (2017) Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy 9:12, pages 1035-1050.
Crossref
Crossref
Nischay K. Rege, Nelson F.B. Phillips & Michael A. Weiss. (2017) Development of glucose-responsive ‘smart’ insulin systems. Current Opinion in Endocrinology, Diabetes & Obesity 24:4, pages 267-278.
Crossref
Crossref
Kenta Haraya, Tatsuhiko Tachibana & Junichi Nezu. (2017) Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metabolism and Pharmacokinetics 32:4, pages 208-217.
Crossref
Crossref
David Russell-Jones, Bruce W. Bode, Christophe De Block, Edward Franek, Simon R. Heller, Chantal Mathieu, Athena Philis-Tsimikas, Ludger Rose, Vincent C. Woo, Anne Birk Østerskov, Tina Graungaard & Richard M. Bergenstal. (2017) Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Diabetes Care 40:7, pages 943-950.
Crossref
Crossref
Carolina Mӧller, Evan Clark, Helena Safavi-Hemami, Anthony DeCaprio & Frank Marí. (2017) Isolation and characterization of Conohyal-P1, a hyaluronidase from the injected venom of Conus purpurascens. Journal of Proteomics 164, pages 73-84.
Crossref
Crossref
Jovan Mihajlović, Pieter Bax, Erwin van Breugel, Hedwig M. Blommestein, Mels Hoogendoorn, Wobbe Hospes & Maarten J. Postma. (2017) Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. Clinical Therapeutics 39:6, pages 1221-1232.e4.
Crossref
Crossref
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov, Mark Dixon, Michael Brewster, Martin Barrett & David MacDonald. (2017) Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. The Lancet Haematology 4:6, pages e272-e282.
Crossref
Crossref
Mathieu Marella, Joe Ouyang, Jonathan Zombeck, Chunmei Zhao, Lei Huang, Robert J. Connor, Kim B. Phan, Michael C. Jorge, Marie A. Printz, Rudolph D. Paladini, Arnold B. Gelb, Zhongdong Huang, Gregory I. Frost, Barry J. Sugarman, Lawrence Steinman, Ge Wei, H. Michael Shepard, Daniel C. Maneval & Paula J. Lapinskas. (2017) PH20 is not expressed in murine CNS and oligodendrocyte precursor cells. Annals of Clinical and Translational Neurology 4:3, pages 191-211.
Crossref
Crossref
Elliot Offman & Andrea N. Edginton. (2016) Pharmacokinetic Time Course Scaling of a Subcutaneously Administered Pegylated Peptide Conjugate for a First-in-Human Investigation. European Journal of Drug Metabolism and Pharmacokinetics 42:1, pages 69-78.
Crossref
Crossref
Li-Jin Hsu, Ming-Fu Chiang, Chun-I Sze, Wan-Pei Su, Ye Vone Yap, I-Ting Lee, Hsiang-Ling Kuo & Nan-Shan Chang. (2016) HYAL-2–WWOX–SMAD4 Signaling in Cell Death and Anticancer Response. Frontiers in Cell and Developmental Biology 4.
Crossref
Crossref
Kuan-Jung Chen, Sabrina Sabrina, Nermeen S. El-Safory, Guan-Chiun Lee & Cheng-Kang Lee. (2016) Constitutive expression of recombinant human hyaluronidase PH20 by Pichia pastoris. Journal of Bioscience and Bioengineering 122:6, pages 673-678.
Crossref
Crossref
Riccardo Caccialanza, Thierry Constans, Paolo Cotogni, Gary P. Zaloga & Alessandro Pontes-Arruda. (2016) Subcutaneous Infusion of Fluids for Hydration or Nutrition. Journal of Parenteral and Enteral Nutrition, pages 014860711667659.
Crossref
Crossref
Linda K. Miars, Michelle Tran & Kimberly Duff. (2016) Practical Considerations for Self-Administration of Subcutaneous Immunoglobulin G Utilizing Recombinant Human Hyaluronidase, an Advanced Method of Subcutaneous Administration. Journal of Infusion Nursing 39:6, pages 359-368.
Crossref
Crossref
Richard L Wasserman, Isaac Melamed, Lisa Kobrynski, Jennifer Puck, Sudhir Gupta, Jennifer Doralt, Marlies Sharkhawy, Werner Engl, Heinz Leibl, David Gelmont & Leman Yel. (2016) Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy 8:10, pages 1175-1186.
Crossref
Crossref
Roman Mathaes, Atanas Koulov, Susanne Joerg & Hanns-Christian Mahler. (2016) Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries. Journal of Pharmaceutical Sciences 105:8, pages 2255-2259.
Crossref
Crossref
Shan Liu, Bo Xie, Wei Wei, Mizhou Hui & Zhiguo Su. (2016) Design and preparation of chimeric hyaluronidase as a chaperone for the subcutaneous administration of biopharmaceuticals. Biochemical Engineering Journal 112, pages 32-41.
Crossref
Crossref
Diane R. Mould & Bernd Meibohm. (2016) Drug Development of Therapeutic Monoclonal Antibodies. BioDrugs 30:4, pages 275-293.
Crossref
Crossref
Richard L. Wasserman, Isaac Melamed, Mark R. Stein, Werner Engl, Marlies Sharkhawy, Heinz Leibl, Jennifer Puck, Arye Rubinstein, Lisa Kobrynski, Sudhir Gupta, Andrew J. Grant, Anoshie Ratnayake, Wendell G. Richmond, Joseph Church, Leman Yel & David Gelmont. (2016) Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. Journal of Clinical Immunology 36:6, pages 571-582.
Crossref
Crossref
Luciano Messina, Jose A. Gavira, Salvatore Pernagallo, Juan D. Unciti-Broceta, Rosario M. Sanchez Martin, Juan J. Diaz-Mochon, Susanna Vaccaro, Mayte Conejero-Muriel, Estela Pineda-Molina, Salvatore Caruso, Luca Musumeci, Roberta Di Pasquale, Angela Pontillo, Francesca Sincinelli, Mauro Pavan & Cynthia Secchieri. (2016) Identification and characterization of a bacterial hyaluronidase and its production in recombinant form. FEBS Letters 590:14, pages 2180-2189.
Crossref
Crossref
Cristina Bagacean, Mihnea Zdrenghea, Adrian Tempescul, Victor Cristea & Yves Renaudineau. (2016) Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. Immunotherapy 8:5, pages 569-581.
Crossref
Crossref
Sarit Assouline, Valeria Buccheri, Alain Delmer, Gianluca Gaidano, Marek Trneny, Natalia Berthillon, Michael Brewster, Olivier Catalani, Sai Li, Christine McIntyre, Pakeeza Sayyed & Xavier Badoux. (2016) Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. The Lancet Haematology 3:3, pages e128-e138.
Crossref
Crossref
Sarah Liptrott, Nathalie Cambon, Natalia Berthillon, Maria Mendoza & Rodney Smith. (2014) Minimization of administration route errors with subcutaneous rituximab. Journal of Oncology Pharmacy Practice 22:1, pages 186-187.
Crossref
Crossref
Katherine L. Gill, Iain Gardner, Linzhong Li & Masoud Jamei. (2015) A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins. The AAPS Journal 18:1, pages 156-170.
Crossref
Crossref
Emily Carne, Mark Ponsford, Tariq El-Shanawany, Paul Williams, Trevor Pickersgill & Stephen Jolles. (2016) Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency. Journal of Clinical Pathology 69:1, pages 87-88.
Crossref
Crossref
Ki Hyun Bae & Motoichi Kurisawa. (2016) Emerging hydrogel designs for controlled protein delivery. Biomaterials Science 4:8, pages 1184-1192.
Crossref
Crossref
Matthias GieseMatthias Giese. 2016. Introduction to Molecular Vaccinology. Introduction to Molecular Vaccinology
233
258
.
Jiunn H. Lin & Weirong Wang. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
10
.
Julia Carlson, Keith Cox, Kylie Bedwell & Mathew Ku. (2015) Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective. International Journal of Nursing Practice 21:S3, pages 1-13.
Crossref
Crossref
Sarit Assouline, Valeria Buccheri, Alain Delmer, Gianluca Gaidano, Christine McIntyre, Michael Brewster, Olivier Catalani, Florence Hourcade-Potelleret, Pakeeza Sayyed & Xavier Badoux. (2015) Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. British Journal of Clinical Pharmacology 80:5, pages 1001-1009.
Crossref
Crossref
Clapton Dias, Bassam Abosaleem, Caroline Crispino, Bing Gao & Adam Shaywitz. (2015) Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects. AAPS PharmSciTech 16:5, pages 1101-1107.
Crossref
Crossref
J-R Azanza, B Sádaba & A Gómez-Guiu. (2014) Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens?. Journal of Oncology Pharmacy Practice 21:5, pages 370-376.
Crossref
Crossref
Keming Xu, Fan Lee, Shujun Gao, Min-Han Tan & Motoichi Kurisawa. (2015) Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab. Journal of Controlled Release 216, pages 47-55.
Crossref
Crossref
Sanna Rosengren, Samuel S. Dychter, Marie A. Printz, Lei Huang, Richard I. Schiff, Hans-Peter Schwarz, John K. McVey, Fred H. Drake, Dan C. Maneval, Don A. Kennard, Gregory I. Frost, Barry J. Sugarman & Douglas B. Muchmore. (2015) Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. The AAPS Journal 17:5, pages 1144-1156.
Crossref
Crossref
H. Michael Shepard. (2015) Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy. Frontiers in Oncology 5.
Crossref
Crossref
Leon Rozen, Kim Duff, Catherine Taggart & Jeanette Scott. (2015) A Missed Opportunity. Journal of Infusion Nursing 38:4, pages 252-253.
Crossref
Crossref
Shiping Fang, Anna-Maria A. Hays Putnam & Michael J. LaBarre. (2015) Kinetic investigation of recombinant human hyaluronidase PH20 on hyaluronic acid. Analytical Biochemistry 480, pages 74-81.
Crossref
Crossref
Andrea Allmendinger, Robert Mueller, Edward Schwarb, Mark Chipperfield, Joerg Huwyler, Hanns-Christian Mahler & Stefan Fischer. (2014) Measuring Tissue Back-Pressure - In Vivo Injection Forces During Subcutaneous Injection. Pharmaceutical Research 32:7, pages 2229-2240.
Crossref
Crossref
Oscar Duems-Noriega & Sergio Ariño-Blasco. (2015) Subcutaneous fluid and drug delivery: safe, efficient and inexpensive. Reviews in Clinical Gerontology 25:2, pages 117-146.
Crossref
Crossref
Jason Seewoodhary & Stephen Phooi Yew Wong. (2015) New insulins for diabetes. Practical Diabetes 32:3, pages 93-98.
Crossref
Crossref
Anas M. Fathallah & Sathy V. Balu-Iyer. (2015) Anatomical, Physiological, and Experimental Factors Affecting the Bioavailability of sc-Administered Large Biotherapeutics. Journal of Pharmaceutical Sciences 104:2, pages 301-306.
Crossref
Crossref
S Jolles, J S Orange, A Gardulf, M R Stein, R Shapiro, M Borte & M Berger. (2015) Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clinical and Experimental Immunology 179:2, pages 146-160.
Crossref
Crossref
R. L. Wasserman. (2014) Subcutaneous immunoglobulin: facilitated infusion and advances in administration. Clinical & Experimental Immunology 178, pages 75-77.
Crossref
Crossref
Wolfgang F. Richter & Björn Jacobsen. (2014) Subcutaneous Absorption of Biotherapeutics: Knowns and Unknowns. Drug Metabolism and Disposition 42:11, pages 1881-1889.
Crossref
Crossref
S. K. Garg, J. B. Buse, J. S. Skyler, D. E. Vaughn & D. B. Muchmore. (2014) Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. Diabetes, Obesity and Metabolism 16:11, pages 1065-1069.
Crossref
Crossref
Hongrui Li, Jing Yang, Yubin Chen, Lili Guan, LinNa Du, YongXin Guo, Wenhui Wang, Lihao Wang, Haiyan Li, Chao Jiang & Xiaokun Li. (2014) Expression of a functional recombinant oleosin-human hyaluronidase hPH-20 fusion in Arabidopsis thaliana. Protein Expression and Purification 103, pages 23-27.
Crossref
Crossref
Daniel Schweizer, Tim Serno & Achim Goepferich. (2014) Controlled release of therapeutic antibody formats. European Journal of Pharmaceutics and Biopharmaceutics 88:2, pages 291-309.
Crossref
Crossref
Laurence JadinLei HuangGe WeiQiping ZhaoArnold B. GelbGregory I. FrostPing JiangH. Michael Shepard. (2014) Characterization of a Novel Recombinant Hyaluronan Binding Protein for Tissue Hyaluronan Detection. Journal of Histochemistry & Cytochemistry 62:9, pages 672-683.
Crossref
Crossref
F. Pinguet & G. Milano. (2014) Biothérapies par voie sous-cutanée : modalités d’absorption et implications cliniquesSubcutaneous dual-therapies: Methods of absorption and clinical implications. Oncologie 16:7-8, pages 393-400.
Crossref
Crossref
Antonio SalarIrit AviviBeate BittnerReda BouabdallahMike BrewsterOlivier CatalaniGeorge FollowsAndrew HaynesFlorence Hourcade-PotelleretAndrea JanikovaJean-François LaroucheChristine McIntyreMichael PedersenJuliana PereiraPakeeza SayyedOfer ShpilbergGayane Tumyan. (2014) Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. Journal of Clinical Oncology 32:17, pages 1782-1791.
Crossref
Crossref
Zhongdong Huang, Chunmei Zhao, Yanling Chen, Jessica A. Cowell, Ge Wei, Anne Kultti, Lei Huang, Curtis B. Thompson, Sanna Rosengren, Gregory I. Frost & H. Michael Shepard. (2014) Recombinant Human Hyaluronidase PH20 Does Not Stimulate an Acute Inflammatory Response and Inhibits Lipopolysaccharide-Induced Neutrophil Recruitment in the Air Pouch Model of Inflammation. The Journal of Immunology 192:11, pages 5285-5295.
Crossref
Crossref
Jihyun Kim, Youhoon Chong & Hyejung Mok. (2014) Shell-Crosslinked Hyaluronic Acid Nanogels for Live Monitoring of Hyaluronidase Activity In Vivo. Macromolecular Bioscience 14:6, pages 881-888.
Crossref
Crossref
Richard L Wasserman. (2014) Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy 6:5, pages 553-567.
Crossref
Crossref
Hanne M. Kinnunen & Randall J. Mrsny. (2014) Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. Journal of Controlled Release 182, pages 22-32.
Crossref
Crossref
S. Halimi, N. Wion, A.-L. Coulon & P.-Y. Benhamou. (2014) Les insulines, ultra-rapides, et techniques pour accélérer l’action des insulines rapides. Médecine des Maladies Métaboliques 8:2, pages 125-132.
Crossref
Crossref
Kensei Tobinai. (2014) Subcutaneous rituximab: a practical approach?. The Lancet Oncology 15:3, pages 254-255.
Crossref
Crossref
Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul, Phillippe Solal-Céligny, Martin Barrett, Claude Berge, Beate Bittner, Axel Boehnke, Christine McIntyre & David MacDonald. (2014) Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. The Lancet Oncology 15:3, pages 343-352.
Crossref
Crossref
Ryan F. Donnelly, Sharifa Al-Zahrani, Marija Zaric, Cian M. McCrudden, Cristopher J. Scott & Adrien Kissenpfenning. 2014. Molecular Vaccines. Molecular Vaccines
697
715
.
Marc D. de Smet & Lisa Grillone. 2014. Vitreous. Vitreous
863
868
.
Vincent Launay-Vacher. (2013) An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs. Cancer Chemotherapy and Pharmacology 72:6, pages 1361-1367.
Crossref
Crossref
Darrell J. Irvine, Xingfang Su & Brandon Kwong. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
48
.
Cheng-Ping Mao, Martin R. Brovarney, Karim Dabbagh, Herbert F. Birnböck, Wolfgang F. Richter & Christopher J. Del Nagro. (2013) Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys. PLoS ONE 8:11, pages e80533.
Crossref
Crossref
D.W. Kang, D.A. Oh, G.Y. Fu, J.M. Anderson & M.L. Zepeda. (2013) Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein. Journal of Pharmacological and Toxicological Methods 67:3, pages 140-147.
Crossref
Crossref
Linda Morrow, Douglas B. Muchmore, Marcus Hompesch, Elizabeth A. Ludington & Daniel E. Vaughn. (2013) Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase. Diabetes Care 36:2, pages 273-275.
Crossref
Crossref
Leonid Kagan & Donald E. Mager. (2013) Mechanisms of Subcutaneous Absorption of Rituximab in Rats. Drug Metabolism and Disposition 41:1, pages 248-255.
Crossref
Crossref
P. Scodeller, P. N. Catalano, N. Salguero, H. Duran, A. Wolosiuk & G. J. A. A. Soler-Illia. (2013) Hyaluronan degrading silica nanoparticles for skin cancer therapy. Nanoscale 5:20, pages 9690.
Crossref
Crossref
Laura L. Kuensting. (2013) Comparing Subcutaneous Fluid Infusion with Intravenous Fluid Infusion in Children. Journal of Emergency Nursing 39:1, pages 86-91.
Crossref
Crossref
Herlinda Clement, Alejandro Olvera, Mabel Rodríguez, Fernando Zamudio, Laura A. Palomares, Lourival D. Possani, George V. Odell, Alejandro Alagón & Rosana Sánchez-López. (2012) Identification, cDNA cloning and heterologous expression of a hyaluronidase from the tarantula Brachypelma vagans venom. Toxicon 60:7, pages 1223-1227.
Crossref
Crossref
Richard L. Wasserman. (2012) Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again. Journal of Clinical Immunology 32:6, pages 1153-1164.
Crossref
Crossref
Hassan Abolhassani, Mohammad Salehi Sadaghiani, Asghar Aghamohammadi, Hans D. Ochs & Nima Rezaei. (2012) Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis. Journal of Clinical Immunology 32:6, pages 1180-1192.
Crossref
Crossref
Richard L. Wasserman, Isaac Melamed, Mark R. Stein, Sudhir Gupta, Jennifer Puck, Werner Engl, Heinz Leibl, Barbara McCoy, Victoria G. Empson, David Gelmont & Richard I. Schiff. (2012) Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. Journal of Allergy and Clinical Immunology 130:4, pages 951-957.e11.
Crossref
Crossref
Anne Kultti, Xiaoming Li, Ping Jiang, Curtis B. Thompson, Gregory I. Frost & H. Michael Shepard. (2012) Therapeutic Targeting of Hyaluronan in the Tumor Stroma. Cancers 4:3, pages 873-903.
Crossref
Crossref
Wolfgang F. Richter, Suraj G. Bhansali & Marilyn E. Morris. (2012) Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration. The AAPS Journal 14:3, pages 559-570.
Crossref
Crossref
Displaying 200 of 230 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list